{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:16:46Z","timestamp":1789676206370,"version":"4.0.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/ftd.0b013e31825dc4a6","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T12:50:06Z","timestamp":1340887806000},"page":"390-397","source":"Crossref","is-referenced-by-count":54,"title":["Concentrations of Stiripentol in Children and Adults With Epilepsy"],"prefix":"10.1097","volume":"34","author":[{"given":"Theodor W.","family":"May","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Boor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Rambeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Holert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Korn-Merker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1517\/13543784.14.7.905","article-title":"Stiripentol.","volume":"14","author":"Chiron","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"R2-6-20210129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2011.03007.x","article-title":"The pharmacologic treatment of Dravet syndrome.","volume":"52","author":"Chiron","year":"2011","journal-title":"Epilepsia"},{"key":"R3-6-20210129","first-page":"154","article-title":". Stiripentol. A novel antiepileptic drug.","volume":"57","author":"Trojnar","year":"2005","journal-title":"Pharmacol Rep"},{"key":"R4-6-20210129","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/j.1552-4604.1983.tb01799.x","article-title":". Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity.","volume":"23","author":"Levy","year":"1983","journal-title":"Clin Pharmacol"},{"key":"R5-6-20210129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/clpt.1984.237","article-title":". Stiripentol kinetics in epilepsy: Nonlinearity and interactions.","volume":"36","author":"Levy","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"R6-6-20210129","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1528-1157.1984.tb03448.x","article-title":". Michaelis-Menten kinetics of stiripentol in normal humans.","volume":"25","author":"Levy","year":"1984","journal-title":"Epilepsia"},{"key":"R7-6-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10309-008-0320-2","article-title":"Stiripentol (Diacomit(R)-eine neue Therapieoption zur Behandlung des Dravet-syndroms (SMEI).","volume":"21","author":"Schweizer","year":"2008","journal-title":"Z Epileptol"},{"key":"R8-6-20210129","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clpt.2004.12.134","article-title":"DAthis P, et al..","volume":"77","author":"Rey","year":"2005","journal-title":"Is pharmacokinetics of stiripentol linear Clin Pharmacol Ther"},{"key":"R9-6-20210129","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","article-title":". Influence of stiripentol on cytochrome p450-mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants.","volume":"62","author":"Tran","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"R10-6-20210129","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","article-title":". In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism.","volume":"34","author":"Giraud","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R11-6-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1528-1157.1991.tb05254.x","article-title":". Carbamazepine dose requirements during stiripentol therapy: Influence of cytochrome p-450 inhibition by stiripentol.","volume":"32","author":"Kerr","year":"1991","journal-title":"Epilepsia"},{"key":"R12-6-20210129","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s002280050147","article-title":". Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children.","volume":"50","author":"Tran","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"R13-6-20210129","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.0306-5251.2003.01919.x","article-title":". Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human.","volume":"56","author":"Cazali","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R14-6-20210129","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","article-title":". Stiripentol: Efficacy and tolerability in children with epilepsy.","volume":"40","author":"Perez","year":"1999","journal-title":"Epilepsia"},{"key":"R15-6-20210129","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":". Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Sticlo study group.","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"R16-6-20210129","first-page":"213","article-title":"Gent JP, et al..","volume":"23","author":"Haigh","year":"1987","journal-title":"N-desmethylclobazam: A possible alternative to clobazam in the treatment of refractory epilepsy Br J Clin Pharmacol"},{"key":"R17-6-20210129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/clpt.1990.144","article-title":". Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid.","volume":"48","author":"Levy","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"R18-6-20210129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","article-title":"Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study.","volume":"21","author":"May","year":"1999","journal-title":"Ther Drug Monit"},{"key":"R19-6-20210129","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","article-title":"Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication.","volume":"24","author":"May","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R20-6-20210129","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FTD.0b013e31820fa9ad","article-title":". Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication.","volume":"33","author":"May","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R21-6-20210129","first-page":"22","article-title":"Longitudinal data analysis using generalized linear models.","volume":"13-","author":"Liang","year":"1986","journal-title":"Biometrika"},{"key":"R22-6-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs.","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"R23-6-20210129","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactions - principles and clinical implications.","volume":"8","author":"Johannessen","year":"2010","journal-title":"Curr Neuropharmacol"},{"key":"R24-6-20210129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/187569209790112382","article-title":". Human genetic variation, population pharmacokineticdynamic models, bayesian feedback control, and maximally precise individualized drug dosage regimens.","volume":"7","author":"Jelliffe","year":"2009","journal-title":"CPPM"},{"key":"R25-6-20210129","first-page":"161","article-title":"Therapeutic drug monitoring of newer antiepileptic drugs.","volume":"35","author":"Brandt","year":"2011","journal-title":"J Lab Med"},{"key":"R26-6-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":". Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31825dc4a6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:39:48Z","timestamp":1620952788000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201208000-00006"}},"subtitle":["The Influence of Dose, Age, and Comedication"],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31825dc4a6","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}